BRPI0606408A2 - tratamento local de defeitos ósseos com matriz que libera bmp ou pth - Google Patents

tratamento local de defeitos ósseos com matriz que libera bmp ou pth

Info

Publication number
BRPI0606408A2
BRPI0606408A2 BRPI0606408-6A BRPI0606408A BRPI0606408A2 BR PI0606408 A2 BRPI0606408 A2 BR PI0606408A2 BR PI0606408 A BRPI0606408 A BR PI0606408A BR PI0606408 A2 BRPI0606408 A2 BR PI0606408A2
Authority
BR
Brazil
Prior art keywords
cysts
matrix
bmp
pth
bone defects
Prior art date
Application number
BRPI0606408-6A
Other languages
English (en)
Inventor
Jason Schense
John Watson
Isabelle Arrighi
Original Assignee
Kuros Biosurgery Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuros Biosurgery Ag filed Critical Kuros Biosurgery Ag
Publication of BRPI0606408A2 publication Critical patent/BRPI0606408A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

TRATAMENTO LOCAL DE DEFEITOS óSSEOS COM MATRIZ QUE LIBERA BMP OU PTH. A presente invenção refere-se a um método de tratamento local de defeitos ósseos específicos tais como osteoporose ou cistos ásseos que compreende a etapa de administração local de uma formulação que compreende um peptídeo de fusão contendo um primeiro domínio que compreende PTH ou BMP 2 ou BMP 7, e um segundo domínio que compreende um domínio de substrato covalentemente reticulado; e um material adequado de formar uma matriz biodegradável adequada para crescimento ou desenvolvimento celular, em que o peptídeo de fusão é covalentemente ligado à matriz. Em uma modalidade a matriz contém um ou mais agentes de contraste, e é preferivelmente formada na ausência de um fator de crescimento. A matriz pode ser usada no tratamento de cistos preenchidos com fluido tais como cistos de Tarlov, cistos ovarianos, cistos aracnóides, cistos de osso aneurismático ou cistos hepáticos.
BRPI0606408-6A 2005-01-06 2006-01-06 tratamento local de defeitos ósseos com matriz que libera bmp ou pth BRPI0606408A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64183005P 2005-01-06 2005-01-06
US64284805P 2005-01-10 2005-01-10
PCT/EP2006/050070 WO2006072623A1 (en) 2005-01-06 2006-01-06 Local treatment of bone defects with matrix releasing bmp or pth

Publications (1)

Publication Number Publication Date
BRPI0606408A2 true BRPI0606408A2 (pt) 2009-06-23

Family

ID=36572036

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606408-6A BRPI0606408A2 (pt) 2005-01-06 2006-01-06 tratamento local de defeitos ósseos com matriz que libera bmp ou pth

Country Status (11)

Country Link
US (1) US8318674B2 (pt)
EP (1) EP1833505B1 (pt)
JP (1) JP2008526811A (pt)
KR (1) KR20070108868A (pt)
AU (1) AU2006204462A1 (pt)
BR (1) BRPI0606408A2 (pt)
CA (1) CA2592877A1 (pt)
ES (1) ES2476996T3 (pt)
MX (1) MX2007008329A (pt)
RU (1) RU2007129845A (pt)
WO (2) WO2006073711A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
MX2007008319A (es) * 2005-01-06 2007-10-04 Kuros Biosurgery Ag Matrices suplementadas para la reparacion de fracturas oseas.
JP5315233B2 (ja) * 2006-05-26 2013-10-16 バクスター・インターナショナル・インコーポレイテッド 注入可能な骨空隙充填剤
AU2007268175B2 (en) 2006-05-26 2013-05-23 Baxter Healthcare S.A. Injectable fibrin composition for bone augmentation
AU2014200027B2 (en) * 2007-03-26 2015-10-29 Baxter Healthcare Sa Injectable void filler for soft tissue augmentation
CA2682034C (en) * 2007-03-26 2015-01-27 Baxter International Inc. Injectable void filler for soft tissue augmentation
CA2930681C (en) * 2007-04-09 2019-10-15 The Board Of Trustees Of The University Of Arkansas Fusion protein of collagen-binding domain and parathyroid hormone
DK2136850T3 (da) * 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
US8062364B1 (en) 2007-04-27 2011-11-22 Knee Creations, Llc Osteoarthritis treatment and device
MX2010003969A (es) * 2007-10-12 2010-06-30 Kuros Biosurgery Ag Composiciones inyectables de fibrina que comprenden sal de estroncio para el aumento de tejidos.
WO2009083544A2 (en) * 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
WO2009144085A2 (en) 2008-04-18 2009-12-03 Kuros Biosurgery Ag Dispensing device, kit containing the device, and method of operating the device
WO2009139525A1 (en) * 2008-05-16 2009-11-19 Industry Foundation Of Chonnam National University An synthetic peptide containing bone forming peptide 1(bfp 1) for stimulating osteoblast differentiation, and pharmaceutical composition comprising the synthetic peptide
US8025872B2 (en) 2008-05-16 2011-09-27 Industry Foundation Of Chonnam National University Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same
EP2303911B1 (en) * 2008-06-20 2012-08-15 Industry Foundation Of Chonnam National University A synthetic peptide consisting of bone forming peptide 2(bfp 2) for stimulating osteoblast differentiation, and pharmaceutical composition comprising the synthetic peptide
EP2311482A1 (en) * 2009-10-12 2011-04-20 Industry Foundation Of Chonnam National University Osteogenic synthetic BMP-7 peptides, pharmaceutical compositions cell culture medium containing same
US9717779B2 (en) * 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
US9579273B2 (en) 2011-12-14 2017-02-28 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
US9550012B2 (en) 2013-08-05 2017-01-24 University Of Notre Dame Du Lac Tissue scaffolds having bone growth factors
WO2016075154A1 (en) * 2014-11-10 2016-05-19 Ethris Gmbh Induction of osteogenesis by delivering bmp encoding rna
GB2545880A (en) * 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
AU2017204355B2 (en) 2016-07-08 2021-09-09 Mako Surgical Corp. Scaffold for alloprosthetic composite implant
WO2018148573A1 (en) 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
EP3536353A1 (en) * 2018-03-09 2019-09-11 Kuros Biosurgery AG Method and kits for producing a fibrin matrix
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
SE8200751L (sv) 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
DE3433210C1 (de) * 1984-09-10 1986-06-05 Hans Dr.med. Dr.med.dent. 8000 München Scheicher Mittel zur Fuellung von Knochen- und Zahndefekten,zum Knochenaufbau,fuer Knochenkontaktschichten und fuer Knochen- und Zahnwurzelersatz und Verwendung von Carbonatapatit fuer diesen Zweck
IL74617A (en) 1985-03-15 1988-11-15 Yeda Res & Dev Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals
AU2258788A (en) 1987-07-07 1989-01-30 Cytrx Biopool Ltd. Fibrin-binding compound and method
US5504001A (en) 1987-11-25 1996-04-02 Zymogenetics, Inc. Hybrid plasminogen activator
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5100668A (en) 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
DE68928532T2 (de) 1988-11-09 1998-05-28 Protein Polymer Tech Inc Funktionelles, durch ein rekombinantes verfahren hergestelltes synthetisches proteinpolymer
US5171670A (en) 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
EP1142581A3 (en) 1990-11-27 2002-09-11 American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
SE9101853D0 (sv) 1991-06-17 1991-06-17 Jonas Wadstroem Improved tissue ashesive
EP0602173B1 (en) * 1991-09-05 1999-05-26 Baxter International Inc. Topical fibrinogen complex
SE470006B (sv) 1991-09-26 1993-10-25 Corline Systems Ab Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5310538A (en) * 1993-03-11 1994-05-10 Sterling Winthrop Inc. Compositions of iodophenoxy alkylene ethers in film-forming materials for visualization of the gastrointestinal tract
CA2158134C (en) 1993-03-12 2010-05-04 Hernan A. Nunez Supplemented tissue sealant
TW303299B (pt) * 1993-07-22 1997-04-21 Lilly Co Eli
US5428014A (en) 1993-08-13 1995-06-27 Zymogenetics, Inc. Transglutaminase cross-linkable polypeptides and methods relating thereto
US5773577A (en) 1994-03-03 1998-06-30 Protein Polymer Technologies Products comprising substrates capable of enzymatic cross-linking
CA2155762C (en) 1994-08-23 2000-04-25 Haruya Sato Protein modification method
JP4223548B2 (ja) 1994-12-07 2009-02-12 ジ・アメリカン・ナショナル・レッド・クロス 補足または非補足組織シーラント、それらの製法および使用
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5693341A (en) 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents
US5561982A (en) 1995-05-02 1996-10-08 Universal Vortex, Inc. Method for energy separation and utilization in a vortex tube which operates with pressure not exceeding atmospheric pressure
WO1997018314A1 (de) 1995-11-16 1997-05-22 Boehringer Mannheim Gmbh Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine
US7026292B1 (en) * 1995-12-12 2006-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
WO1997022371A1 (en) 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
US5874308A (en) 1996-01-16 1999-02-23 University Of British Columbia Compositions and methods for modulating cell proliferation using growth factor-polysaccharide binding fusion proteins
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6026957A (en) * 1996-03-27 2000-02-22 The Procter & Gamble Company Flexible paper covered package and process for producing same
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
CN1231675A (zh) 1996-09-26 1999-10-13 味之素株式会社 修饰的生理活性蛋白及含有该蛋白的药物组合物
DE19882746T1 (de) 1997-04-03 2001-10-18 California Inst Of Techn Enzymvermittelte Modifikation von Fibrin für das Gewebs-Engineering
PL341209A1 (en) 1997-12-18 2001-03-26 Lilly Co Eli Crystalline teriparatide
US5958874A (en) 1998-02-18 1999-09-28 The Research Foundation Of State University Of New York Recombinant fibronectin-based extracellular matrix for wound healing
DE19816858A1 (de) 1998-04-16 1999-10-21 Merck Patent Gmbh Tricalciumphosphathaltige Biozementpasten mit Kohäsionspromotoren
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
DK1181323T3 (da) 1999-02-01 2011-10-17 Eidgenoess Tech Hochschule Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
ES2255257T3 (es) 1999-04-22 2006-06-16 Eidgenossische Technische Hochschule (Eth) Liberacion controlada de factores de crecimiento a partir de matrices que contienen heparina.
CA2377435A1 (en) * 1999-06-29 2001-01-04 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
US7052856B2 (en) 1999-10-05 2006-05-30 The Regents Of The University Of California NELL-1 enhanced bone mineralization
DE20010297U1 (de) 2000-06-08 2000-08-31 ETH Zürich, Zürich Enzymvermittelte Modifizierung von Fibrin zur Gewebemanipulation: Fibrin-Formulierungen mit Peptiden
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
WO2002085422A1 (en) 2001-04-25 2002-10-31 Eidgenössische Technische Hochschule Zürich Drug delivery matrices to enhance wound healing
KR101054023B1 (ko) * 2001-11-07 2011-08-04 아이드게노시셰 테크시셰 호흐쉘 취리히 세포 내증식 및 조직 재생을 제어하기 위한 합성 매트릭스
JP4560291B2 (ja) 2001-12-18 2010-10-13 イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ 組織操作のための成長因子改変タンパク質マトリクス
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003055418A1 (en) 2001-12-21 2003-07-10 Lagow Richard J Calcium phosphate bone replacement materials and methods of use thereof
EP1494730B1 (en) * 2002-03-22 2012-01-18 Kuros Biosurgery AG Composition for hard tissue augmentation
CA2483778A1 (en) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
US20040002770A1 (en) * 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
EP1592463B1 (en) 2003-02-13 2006-08-16 SYNTHES AG Chur Injectable bone-replacement mixture
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
DE10355992A1 (de) 2003-11-27 2005-06-30 Curasan Ag Bioresorbierbares Kompositmaterial
US20060147443A1 (en) * 2004-12-22 2006-07-06 Kuros Biosurgery Ag Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages

Also Published As

Publication number Publication date
MX2007008329A (es) 2008-01-16
WO2006072623A1 (en) 2006-07-13
WO2006073711A2 (en) 2006-07-13
ES2476996T3 (es) 2014-07-15
EP1833505A1 (en) 2007-09-19
WO2006073711A3 (en) 2007-03-01
US20070010440A1 (en) 2007-01-11
JP2008526811A (ja) 2008-07-24
AU2006204462A1 (en) 2006-07-13
US8318674B2 (en) 2012-11-27
KR20070108868A (ko) 2007-11-13
EP1833505B1 (en) 2014-04-02
RU2007129845A (ru) 2009-02-20
CA2592877A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
BRPI0606408A2 (pt) tratamento local de defeitos ósseos com matriz que libera bmp ou pth
Fu et al. Enhancing cell proliferation and osteogenic differentiation of MC3T3-E1 pre-osteoblasts by BMP-2 delivery in graphene oxide-incorporated PLGA/HA biodegradable microcarriers
Byambaa et al. Bioprinted osteogenic and vasculogenic patterns for engineering 3D bone tissue
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
Wilkinson et al. Biomimetic microtopography to enhance osteogenesis in vitro
Su et al. Preparation of Decellularized Triphasic Hierarchical Bone‐Fibrocartilage‐Tendon Composite Extracellular Matrix for Enthesis Regeneration
BRPI0507239A (pt) composição de revestimento para a formação de uma camada inorgánica sobre a superfìcie de um substrato, e, processos para prover um revestimento despoluente e/ou limpeza de sujeiras em um substrato e para evitar e/ou tratar mìldios, bolores, algas e/ou bactérias sobre um substrato
Gu et al. Degradation, hemolysis, and cytotoxicity of silane coatings on biodegradable magnesium alloy
Shi et al. Directing osteogenesis of stem cells with drug‐laden, polymer‐microsphere‐based micropatterns generated by teflon microfluidic chips
CU23831B1 (es) Compuestos de pirrolo-pirimidina
CL2008002269A1 (es) Composicion util para tratar plantas, que comprende un medio oleoso que contiene particulas de 1- metil - ciclopropeno encapsulado por un agente encapsulador, siendo dichas particulas de 50 micrometros o menos y donde el medio oleoso comprende ademas uno o más dispersante.
BR122020000059B8 (pt) composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
ATE510570T1 (de) Mikroverkapselte zusammensetzungen zur endoluminalen geweberekonstruktion
BR0317122A (pt) Artigo absorvente que contém um substrato de carbono ativado
PE20070939A1 (es) Concentracion de suspensiones
ECSP088638A (es) Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
CL2007002371A1 (es) Metodo para administrar un agente terapeutico que comprende administrar una composicion de nanoparticulas que comprende una matriz polimerica junto con un cation divalente que contiene un agente terapeutico; y dicha composicion.
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
Vahidi et al. Microfluidic-based strip assay for testing the effects of various surface-bound inhibitors in spinal cord injury
ECSP088178A (es) Agente quelante para fertilizantes de micronutrientes
CL2007002392A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hiperplasia prostatica benigna, enfermedad de barrett, asma, enfermedad de crohn, reparacion de musculo esqueletico y tendon, colitis ulcerosa y leishmaniasis.
AR112818A1 (es) Fabricación de composiciones farmacéuticas que comprenden uno o más de estos: un péptido, una proteína y un anticuerpo
BR112018008388A2 (pt) composição compreendendo uma matriz para transferência melhorada de moléculas osteoindutoras em reparo ósseo, implante ósseo, kit e uso
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
BR0300120A (pt) Composição de resposta disparada, e, dispositivo e processo para a liberação disparada de um ou mais ingredientes ativos para um sistema aquoso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.